To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors

NCT06752681 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

254

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced or Metastatic Solid Tumors

Interventions

DRUG: DAY301

Sponsor

Day One Biopharmaceuticals, Inc.